Navigation Links
Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms

MONTREAL, Dec. 5, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that the company has reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A.  Under the terms of the revised agreement, Galderma will continue to supply Restylane® and Perlane® to Valeant, under the terms and conditions Galderma currently supplies those products to Medicis Pharmaceutical Corporation (NYSE: MRX).  In addition, Valeant will make an upfront payment and a royalty to Galderma on sales of Sculptra®.  Among other things, the agreement provides for resolution of all claims asserted in Galderma's pending litigation relating to Valeant's acquisition of Medicis. 

In addition, Valeant will obtain North American rights to Emervel®, an innovative, next generation family of hyaluronic acid dermal fillers that are specifically designed to provide both patient tolerability and long-lasting correction of facial lines, contouring and volume loss or lip enhancement.  The terms of the agreement are subject to the closing of Valeant's pending acquisition of Medicis, which is expected to occur on December 11, 2012.

"We are pleased to have found a collaborative solution with Galderma to create a long-term working relationship between our two companies," said J. Michael Pearson, chairman and chief executive officer.  "The combination of Restylane, Perlane and Sculptra, along with the future addition of Emervel, delivers a broad and strong array of aesthetic product offerings for doctors and patients. With this agreement, Valeant and Galderma will continue to build a leading aesthetics presence in North America."

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at

Forward-Looking Statements

This press release may contain forward-looking statements. These forward-looking statements relate to, among other things, the closing of the Medicis transaction, the final resolution of existing litigation, and the addition of Emervel to the product portfolio. Forward-looking statements can generally be identified by the use of words such as "believe," "anticipate," "expect," "estimate," "intend," "continue," "plan," "project," "will," "may," "should," "could," "would," "target," "potential," and other similar expressions.  In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.  Actual results may differ materially from those expressed or implied in such statements.  Important factors that could cause actual results to differ materially from these expectations include, among other things, the satisfaction of customary closing conditions with respect to the closing of the Medicis transaction, the approval by FDA of Emervel and the addition of Emervel to the product portfolio, and the risk factors as detailed from time to time in Valeant's reports filed with the Securities and Exchange Commission and the Canadian Securities Administrators. 


Contact Information:
Laurie W. Little

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces New Management Appointments
2. Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results
3. Valeant Pharmaceuticals Annonces New $1.5 Billion Securites Repurchase Program
4. Valeant Pharmaceuticals Receives FTC Clearance For Medicis Acquisition
5. Valeant Pharmaceuticals Reports 2012 Third Quarter Financial Results
6. Valeant Pharmaceuticals Reschedules Its Third Quarter 2012 Financial Results Webcast And Conference Call To November 2, 2012 Due To Hurricane Sandy
7. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
8. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals To Syndicate Incremental Loans
11. Valeant Pharmaceuticals Announces Management Change
Post Your Comments:
(Date:11/26/2015)... ) has ... Future Horizons and Growth Strategies in the ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> ) has announced the ... and Growth Strategies in the French Drugs ...
(Date:11/26/2015)... November 26, 2015 ... universitetssjukhus ser potential att använda SyMRI för ... för patienter med multipel skleros (MS) ... med SyntheticMR AB för att kunna använda ... sjukhuset. Med SyMRI kan man generera flera ...
(Date:11/26/2015)... India , November 26, 2015 ... --> adds ... Report" and "Investigation Report on China ... and 2021 forecasts data and information ... . ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials of ... Narconon network, announced the release of a new cutting edge recovery program that has ... been working with drug- and alcohol-addicted individuals with the purpose to free addicts from ...
(Date:11/25/2015)... ... , ... Smiles by Stevens is pleased to announce the addition ... many patients are aware of the benefits of Botox® in the treatment of moderate ... with discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) ...
(Date:11/25/2015)... ... , ... In an ongoing Clinical Study conducted by an independent physician, Andrew ... is evaluating the efficacy of its product and its disinfection protocol. This study is ... May 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in ...
(Date:11/25/2015)... Silver Spring, Md (PRWEB) , ... November 25, ... ... the Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups ... the history of this disease. The Periwinkle Pioneers, nominated by the public, will ...
Breaking Medicine News(10 mins):